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Abstract  
Diaphragm disease in advanced ovarian cancer: predictability of pre-operative imaging and safety of surgical 
intervention 
Rachel Pounds, Andrew Phillips, Sean Kehoe, James Nevin, Sudha Sundar, Ahmed Elattar, Hong Giap Teo, Kavita 
Singh, Janos Balega 
 
Objectives: To establish the positive predictive values of pre-operative identification with CT imaging of 
metastatic diaphragm disease in surgically managed cases of advanced ovarian cancer (AOC). Additionally, we 
have assessed the post-operative morbidity and survival following diaphragmatic surgical intervention in a large 
regional cancer centre in the United Kingdom.   
 
Study design: A retrospective review of all cases of AOC with metastatic diaphragm disease surgically treated at 
the Pan-Birmingham Gynaecological Cancer Centre, UK between 1st August, 2007 and 29th February, 2016.  
 
Results: A total of 536 women underwent surgery for primary AOC. Diaphragm disease was evident intra-
operatively in 215/536 (40.1%) and 85/536 women (15.9%) underwent a procedure involving their diaphragm. 
Of these 85 cases, 38 peritoneal strippings (38/85, 44.7%), 31 partial diaphragmatic resections (31/85, 35.6%) 
and 16 electro-surgical ablations (16/85, 18.9%) were performed. There were no significant differences in post-
operative complications between the three different diaphragmatic surgical groups. Of those patients who 
underwent peritoneal stripping or partial diaphragm resection, 12% were upstaged to stage 4B by virtue of 
pleural invasion. 
 
The positive predictive value for pre-operative radiological identification of diaphragmatic disease was 78.6%. 
CT imaging failed to detect diaphragmatic involvement despite obvious diaphragm disease during surgery in 
29.4% of cases, giving a low negative predictive value of 64.8%. The sensitivity and specificity for CT imaging 
in detecting diaphragm disease was 44.3% and 93.8%, respectively. 
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Conclusions: Diaphragmatic disease is often discovered in AOC. However, pre-operative assessment with CT 
imaging is not reliable in accurately detecting diaphragm involvement. Therefore, all patients with AOC should 
be regarded as in potential need for diaphragm surgery and their operation undertaken in cancer centres with 
adequate expertise in upper abdominal surgery. If there is a suspicion of diaphragm muscle invasion during 
diaphragmatic peritonectomy, the muscle should be partially resected. This will lead to potential upstaging of 
disease to stage 4B and therefore, to suitability for targeted therapy. In our Centre, the surgical removal of 
diaphragmatic disease did not significantly increase surgical morbidity.  
 
Keywords: advanced ovarian cancer, cytoreductive surgery, diaphragm metastases, diaphragmatic resection, 
diaphragmatic peritoneal stripping 
 
 
 
Introduction  
Survival in advanced ovarian cancer (stage 3B, 3C and 4 ovarian, tubal and peritoneal cancer – AOC) is dependent 
on residual disease following cytoreductive surgery [1-3]. Eliminating all macroscopic disease in the peritoneal 
cavity leads to improved prognosis in AOC and therefore, complete cytoreduction (zero macroscopic residual 
disease) is the key surgical aim of AOC treatment [4-8]. Cytoreduction rates in AOC have increased following the 
addition of upper abdominal surgical procedures, thereby improving survival in patients who would otherwise 
be rendered suboptimally cytoreduced [2, 6, 9]. 
 
Upper abdominal metastatic disease typically occurs via transcoelomic spread, through the transfer of malignant 
cells in peritoneal fluid and by direct extension of disease along peritoneal surfaces [6, 10]. There is a high 
incidence of diaphragm involvement in AOC [7]. In the EORTC 55971 study, diaphragmatic disease was seen in 
71.0% and 42.3% of women with AOC during primary and interval debulking surgery, respectively [11]. 
 
Despite the frequency of diaphragmatic disease, it remains one of the common barriers to both optimal and 
complete cytoreduction [4, 5, 7, 12]. Although the surgical resection of metastatic disease has been 
demonstrated to significantly increase 5-year survival in AOC [13], only 30% of gynaecological oncologists in the 
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United Kingdom would treat diaphragm involvement upon detection [14]. Diaphragmatic surgery has a crucial 
role in cytoreduction and has acceptable and manageable complication and morbidity rates reported in the 
literature [10, 15, 16]. 
 
Questions remain as to the accuracy of pre-operative identification with CT imaging of metastatic diaphragm 
disease. The purpose of this study was to determine the positive predictive value (PPV) of preoperative imaging 
as well as the proportion of CT scans with false negative results in cases who underwent cytoreductive surgery. 
Additionally, we have assessed the post-operative morbidity and survival following treatment in a large regional 
cancer centre in the United Kingdom.   
 
Materials and Methods 
A retrospective review was performed of all women with diaphragm metastasis who underwent surgery for AOC 
at the Pan-Birmingham Gynaecological Cancer Centre (PBGCC) between August 2007 and February 2016. Cases 
were identified from the centre’s prospective database. Women were categorised as per the type of diaphragm 
surgery performed: (1) total peritonectomy with partial diaphragmatic resection, (2) total peritonectomy, (3) 
electrosurgical ablation/minor peritoneal resection. Patients who underwent surgery, either received (1) 
primary surgery followed by six cycles of adjuvant chemotherapy or (2) imaging-guided biopsy followed by three 
or four cycles of neoadjuvant chemotherapy (NACT) and subsequent interval debulking surgery (IDS) with three 
cycles of adjuvant chemotherapy. The pre-operative CT scans for all women with AOC in our cohort were 
reviewed and diaphragm involvement evaluated. In those patients who underwent IDS, pre-operative CT 
scans were undertaken upon completion of NACT.  
 
Diaphragm surgery was performed via a recognised approach [17]. If the peritoneal disease was deeply 
invading into the muscle layer, partial diaphragmatic resection was carried out. In the small number of cases 
with superficially invasive peritoneal deposits, partial resection or fulguration was carried out without formal 
peritonectomy. All surgical specimens were assessed by gynaecological oncology histopathologists.  Complete 
cytoreduction (R0) was achieved when there was no macroscopic disease remaining following surgery. When 
disease less than 1cm remained, women were classed as being optimally (R1) cytoreduced and sub-optimally 
AC
CE
PT
ED
 M
AN
US
CR
IPT
(R2) cytoreduced when residual disease was greater than 1cm. Retroperitoneal lymph nodes were only 
removed if found enlarged during exploration [18].  
 
We determined whether there was suspicion of disease on the pre-operative imaging reported by specialist 
gynaecological oncology radiologists. Intra and post-operative complications were categorised as per the Dindo 
grading system [19]. Complications in women who underwent diaphragmatic surgery were directly compared 
to control patients who did not have a diaphragmatic procedure. Cases were matched for surgery type, surgical 
complexity score, disease stage, age and ASA grade.  
 
Positive (PPV) and negative (NPV) predictive values were calculated by comparing suspicion of diaphragm 
disease on pre-operative imaging to histopathological confirmation of disease from surgical specimens. 
Categorical variables were analysed using the Chi-squared test and continuous variables were analysed using 
the Kruskal-Wallis test. The p-values less than 0.05 were regarded as statistically significant. The Kaplan-Meier 
method was used to estimate survival with survival compared using the Mantel-Cox data and was performed 
using IBM SPSS statistics version 22. 
 
Results 
In total, 746 women were diagnosed with AOC at the PBGCC between August 2007 and February 2016. Of 
these, 536 women (71.8%) underwent cytoreductive surgery. At definitive surgical intervention, 
diaphragmatic involvement was detected in 215 women (215/536, 40.1%). Diaphragm surgery was performed 
in 85 of these 215 women (85/215, 39.5%). Of the 130 women whose diaphragm disease was not surgically 
removed, 89.2% (116/130) were found to have widespread unresectable disease, while the remaining were 
unable to tolerate an ultra-radical procedure.  
Overall, in our operated cohort a procedure involving the diaphragm was performed in 15.9% of women 
(85/536). The proportion of women who had diaphragm surgery at the PBGCC has increased over the last nine 
years, from 1.6% in 2007-2008 to 20.7% in 2015-2016.  
 
Sixteen women (16/85, 18.9%) had ablation or a minor peritoneal resection of their diaphragmatic disease, 38 
(38/85, 44.7%) had stripping of the whole diaphragmatic peritoneum and 31 (31/85, 36.5%) had partial 
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diaphragmatic resection with total peritonectomy. There was no significant difference with regards to age, BMI, 
histology, organ of origin, stage or grade of disease between the three diaphragm surgical groups (Table 1). As 
expected, those who had more aggressive diaphragmatic surgery (resection and peritoneal stripping, compared 
to ablation and minor procedures) had high surgical complexity scores (P = 0.0172). Complete cytoreduction was 
achieved in 77 of the 85 women (90.6%). This was independent of the type of diaphragmatic procedure 
undertaken. Patients were significantly more likely to achieve complete cytoreduction following diaphragm 
surgery compared to those who did not undergo a diaphragmatic procedure (P < 0.001).   
 
Identification of diaphragmatic disease 
Pre-operative CT scans were available for 507 patients. There was no evidence of diaphragm disease on both 
pre-operative imaging and intra-operative inspection in 274/507 cases (true negatives, 54.0%).  Although 
diaphragmatic involvement was not suspected on imaging in a further 149 patients, it was detected intra-
operatively (false negatives, 29.4%), creating a NPV of 64.8% (Table 2). Diaphragm disease was identified on 
the imaging of the remaining women. This was correctly identified in 66/507 women (13.0%, true positives), 
while 18/507 were found to have no diaphragm involvement (3.6%, false positives). This gave a PPV of 78.6%.  
 
In 50% of cases that were incorrectly suspected of having diaphragm involvement (false positives), liver 
surface disease was identified adjacent to the diaphragm with no diaphragm involvement. Of those scans that 
failed to detect diaphragm disease (false negatives), liver involvement was evident on 20.8% of scans and 
disease involving both the liver and diaphragm was discovered surgically in 12.8%.  
 
Following intra-operative identification of diaphragmatic disease, 69 women underwent diaphragm stripping or 
resection. Complete radiology and histology results were available for 61. Histopathological examination 
confirmed disease in 60 of these 61 cases (98.4%). Diaphragm involvement was correctly identified with imaging 
in 27/60 women (45.0%), however CT scans failed to detect disease in 33/60 cases (55.0%). In one patient, 
diaphragm disease was suspected on both pre-operative imaging and intra-operative inspection yet was not 
identified during histopathological examination. Of the 38 women who underwent peritoneal stripping, 19 
(50.0%) were found to have disease infiltration through the peritoneum into deeper structures (Table 3). 
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Following full thickness partial diaphragm resection, eight (8/31, 25.8%) women were upstaged after pleural 
invasion was detected and they were identified as having stage 4B disease.  
 
Additional procedures and post-operative morbidity 
Additional surgical procedures undertaken alongside diaphragmatic surgery are described in Table 4. Along with 
the standard operation (total abdominal hysterectomy, bilateral salpingo-oopherectomy and omentectomy) and 
diaphragmatic surgery, additional procedures were performed in 79/85 (92.9%) women. Fifty-three (53/85, 
62.4%) women had more than one additional surgical intervention. 
 
The number of patients who suffered post-operative complications are shown in Table 4. Of the 85 patients who 
underwent diaphragm surgery, 27 (31.8%) did not develop any complication. Grade 3 or higher complications 
(Table 5). Complications specific to diaphragmatic surgery occurred in five patients (5/85, 5.9%), two of which 
(2/85, 2.4%) were grade 3 or higher. Three patients (3/85, 3.5%) suffered pleural effusions (one required 
drainage) and two (2/85, 2.4%) were diagnosed with a pneumothorax. There was no significant difference in 
morbidity or in diaphragm-specific complications between the different diaphragmatic surgical groups. The 
overall return to theatre rate was 7.1% (6/85), none of which were related to the procedures on diaphragm. 
 
Diaphragmatic surgery cases were compared to matched control patients who did not undergo a 
diaphragmatic procedure (Table 6). There was no significant difference in the number or severity of 
complications between those that had diaphragm surgery and their matched controls (P = 0.8728). 
 
There was no statistical difference in the incidence of grade 3+ complications (P = 0.9228) in those who 
underwent standard procedures plus diaphragm surgery only compared to those who had additional 
procedures. However, women who underwent an additional splenectomy were statistically more likely to suffer 
such a complication (P = 0.0491). Two women were readmitted to hospital within eight weeks (2/85, 2.4%). 
There were two cases of mortality within thirty days of diaphragm surgery (2.4%), one secondary to a pulmonary 
embolism and another due to pancreatitis and acute respiratory distress syndrome. Survival data was available 
for 83 women; the median overall survival of those with surgically treated diaphragm disease was 46.9 (95%CI 
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39.8-54.0) months, comparing to a median overall survival of 42.84 months for all 536 patients during our study 
period.  
 
Discussion 
Our cohort of 536 patients with AOC, of which 215 had diaphragm involvement and 85 underwent 
diaphragmatic surgery, is one of the largest published on patients managed in the UK and is the only paper 
with complete denominator descriptors [21]. Since advanced surgical procedures have been introduced at our 
Cancer Centre, the rate of diaphragmatic surgery has increased from 1.6% to 20.7%. Such trends have been 
also seen in our proportion of splenectomies performed previously [22]. The use of advanced surgical 
procedures requires both operative experience and patients where the addition of such advanced procedures 
will improve outcomes. Therefore, diaphragmatic surgery should not be performed in isolation, but as part of 
a “total surgical package” for effective cytoreduction. 
 
The incidence and variation of the different diaphragmatic surgical procedures performed in our series differs 
to other published cohorts. The rates of diaphragm surgery are typically greater amongst cohorts of primary 
debulking cases only; expected due to increased diaphragmatic involvement in those who have not undergone 
neoadjuvant chemotherapy [11, 23]. Fanfani, et al. [6] describe 234 patients who underwent surgery for AOC; 
37.2% had diaphragm surgery. Of these, peritonectomy was performed in 64.4% and partial resection in 14.9%, 
compared to 44.7% and 36.5% in our cohort, respectively. Recently, Turnbull, et al. [24] reported 64 cases of 
diaphragmatic surgical procedures; just 10.9% underwent a resection. With regards to electrosurgical ablation, 
there has been a move towards resection of disease rather than fulguration, perhaps explaining the variation in 
our electrosurgical ablation rate compared to others like Tsolakidis [10] and Fanfani [6], where 22% and 20.7% 
had coagulation alone. 
 
However, these studies fail to describe their patient denominator data, which is essential for meaningful 
assessment of surgical outcomes. A more selective approach to surgical candidates will increase the 
diaphragmatic resection rate as only the fittest with localised disease receive surgery. The Pan-Birmingham 
Gynaecological Cancer Centre has a high operated patient rate of 71.8% compared to the 56% that appears 
standard in the UK [25]. It is likely that patients with extensive upper abdominal disease in other centres may 
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not receive assessment for cytoreductive surgery. We suggest that patient denominator data should be an 
essential criterion for any centre outcomes regarding cytoreductive surgery [21]. 
 
Complex surgical procedures are only undertaken in our Centre when it is expected that complete cytoreduction 
will be achieved. The R0 rate of 90.6%, with the highest rate in the diaphragm resection group (30/31, 96.8%), 
was not unexpected and is consistent with the literature [8, 15]. Despite most women in our cohort undergoing 
other surgical procedures, there was no increase in postoperative morbidity associated with the addition of 
diaphragmatic surgery. However, a splenectomy combined with diaphragmatic surgery demonstrated a 
significant increase in the number of grade 3+ complications, contrary to other reports [22].  
 
A total of 31.8% of patients did not experience a post-operative complication following diaphragm surgery; 
however, it is possible that minor complications were under-reported. Our overall rate of pulmonary 
complications was 5.9% and compares favourably to other published series [4-7, 10, 15, 16, 26-28]. This may 
reflect the proportion of women having surgery after neoadjuvant chemotherapy, who are selected for such at 
the multi-disciplinary team meeting. Several studies [11, 21, 29-31] have demonstrated significantly lower 
complication rates when neoadjuvant chemotherapy is used, and our approach is now supported by the joint 
statement of the Society of Gynecologic Oncologists and the American Society of Clinical Oncologists [32, 33]. 
 
There is little existing data that evaluates the radiological identification of AOC. Soleymani, et al. [27] have 
recently reported their series of diaphragmatic surgery, performed due to suspicion following CT imaging as well 
as intraoperative findings.  Peritoneal disease was confirmed histologically in 96% of cases, with muscle and 
pleural invasion in 28% and 19%, respectively. In our cohort, radiologists under-diagnosed diaphragmatic 
disease: false negative results were common, resulting in a poor NPV and low sensitivity. This may be 
explained by the technical limitation of CT imaging, as low volume disease is not appreciated. With the 
absence of surrounding ascitic fluid, diaphragmatic disease applied to the adjacent liver surface could be 
mistaken as liver surface or subcapsular disease (examples shown in Figures 1-3). In view of this, we should 
retain an element of suspicion in the context of a negative scan and consider the possibility of diaphragm 
involvement where liver disease is evident adjacent to the diaphragm. All AOC cytoreductive surgical cases 
AC
CE
TE
D M
AN
US
CR
IPT
should be regarded as potentially ultra-radical procedures and should only be performed in adequately 
resourced cancer centres with availability of expertise in upper abdominal surgery.  
 
A significant proportion of patients (12%) with obvious diaphragm disease identified during surgery were 
upstaged to FIGO stage 4B as disease was found on the pleural surface. We have a low threshold for diaphragm 
resection when peritonectomy becomes technically impeded, as this is often a sign of muscular invasion. 
Resection of the diaphragmatic muscle will reveal an increased percentage of patients with stage 4B disease, 
who in the UK would subsequently become suitable for targeted therapies.  
 
Conclusion 
Pre-operative imaging has limited value in confirming diaphragmatic disease in women presenting with AOC. As 
such, women undergoing surgery for AOC should be counselled as to the possibility of requiring diaphragmatic 
surgical procedures. Centres equipped to care for these women, with a gynaecological oncology team having 
the necessary surgical expertise and access to other surgical specialities if required, seems the logical place for 
such operations to be concentrated. When undertaken in such centres, the surgical removal of diaphragmatic 
disease does not increase the risk of significant post-operative morbidity. It is essential for centres reporting 
outcomes to reveal the complete denominator data to allow accurate interpretation of surgical outcomes and 
to allow subsequent metanalysis of their data. 
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Figures 
Figure 1. (a) Pre-chemotherapy coronal CT image of the abdomen in a patient with high grade serous 
mullerian adenocarcinoma of the ovary shows metastatic nodules (white arrows) involving the right 
hemidiaphragm. There is also a plaque-like metastasis on the under-surface of the left hemidiaphragm (black 
arrow). The presence of ascites (yellow star) enables easier visualisation of the diaphragmatic metastases as 
separate from the adjacent liver surface. (b) Coronal CT image post 3-cycle neoadjuvant chemotherapy shows 
partial treatment response with residual diaphragmatic disease (black and white arrows). The ascites has 
resolved. 
Figure 2. (a) Coronal and (b) right para-median sagittal CT images of the abdomen in a patient with stage 4 
ovarian cancer post 3-cycle chemotherapy show a persistent bulky subphrenic metastasis (white star) with 
invasion of the liver parenchyma (black star). The mass is broad-based against and not separable from the right 
hemidiaphragm on CT imaging, which is surgically confirmed diaphragmatic disease. 
Figure 3. Axial CT image of the upper abdomen in a patient presenting with a bulky irregular solid adnexal 
mass and large volume ascites. There are nodular soft-tissue abnormalities (white arrows) on the under-
surface of the right hemidiaphragm consistent with metastatic deposits, which are seen separately from the 
liver surface.  
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Figure 1(a) Pre-chemotherapy coronal CT image of the abdomen in a patient with high grade serous 
mullerian adenocarcinoma of the ovary shows metastatic nodules (white arrows) involving the right 
hemidiaphragm. There is also a plaque-like metastasis on the under-surface of the left hemidiaphragm 
(black arrow). The presence of ascites (yellow star) enables easier visualisation of the diaphragmatic 
metastases as separate from the adjacent liver surface. (b) Coronal CT image post 3-cycle neoadjuvant 
chemotherapy shows partial treatment response with residual diaphragmatic disease (black and white 
arrows). The ascites has resolved. 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 a. 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 b. 
Figure 2(a) Coronal and (b) right para-median sagittal CT images of the abdomen in a patient with 
stage 4 ovarian cancer post 3-cycle chemotherapy show a persistent bulky subphrenic metastasis 
(white star) with invasion of the liver parenchyma (black star). The mass is broad-based against and 
not separable from the right hemidiaphragm on CT imaging, which is surgically confirmed 
diaphragmatic disease. 
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Figure 3 Axial CT image of the upper abdomen in a patient presenting with a bulky irregular solid 
adnexal mass and large volume ascites. There are nodular soft-tissue abnormalities (white arrows) on 
the under-surface of the right hemidiaphragm consistent with metastatic deposits, which are seen 
separate from the liver surface.  
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Tables 
 
Table 1: Population characteristics, pathology results and surgical outcomes 
  
 Diaphragmatic 
resection 
N=31 (36.5%) 
Peritoneal 
stripping 
N=38 (44.7%) 
Ablation  
 N=16 
(18.9%) 
P Value Rest of 
patients  
N=451  
Age (years)  
(Mean ± SD) 
58.6 ± 10.1 60.3 ± 9.5 62.0 ± 12.8 0.3679 63.5 ± 2.38 
ASA  
(Median ± IQR) 
2 (1.5-2) 2 (2-3) 2 (2-2.5)  0.3230 2 (2-3) 
BMI    
(Median ± IQR) 
25.5 (23-28.5) 25.5 (21-28.5) 26 (22-29) 0.3679 26 (22-29) 
Stage 
   3B 
   3C 
   4 
n (%) 
1 (3.2) 
15 (48.4) 
15 (48.4) 
n (%) 
2 (5.3) 
29 (76.3) 
7 (18.4) 
n (%) 
4 (25.0) 
8 (50.0) 
4 (25.0) 
0.0305 n (%) 
56 (12.4) 
289 (64.1) 
106 (23.5) 
Organ of Origin  
   Ovary 
   Peritoneum 
   Fallopian Tube 
n (%) 
16 (51.6) 
3 (9.7) 
12 (38.7) 
n (%) 
27 (71.1) 
4 (10.5) 
7 (18.4) 
n (%) 
11 (68.8) 
2 (12.5) 
3 (18.8) 
0.8312 n (%) 
318 (70.5) 
78 (17.3) 
55 (12.2) 
Grade 
   Low (G1) 
   High (G2-3) 
n (%) 
2 (6.5) 
29 (93.5) 
n (%) 
4 (10.5) 
34 (89.5) 
n (%) 
0 (0.0) 
16 (100.0) 
0.4473 n (%) 
17 (3.8) 
434 (96.2) 
Histological  
Sub-type 
   Serous 
   Clear cell 
   MMT 
Undifferentiate
d 
n (%) 
 
28 (90.3) 
0 (0.0) 
3 (9.7) 
0 (0.0) 
n (%) 
 
35 (92.1) 
0 (0.0) 
2 (5.3) 
1 (2.6) 
n (%) 
 
15 (93.8) 
1 (6.3) 
0 (0.0) 
0 (0.0) 
0.2642 n (%) 
 
391 (86.7) 
20 (4.4) 
28 (6.2) 
12 (2.7) 
Surgery Type  
   Primary 
   IDS 
n (%) 
12 (38.7) 
19 (61.3) 
n (%) 
12 (31.6) 
26 (68.4) 
n (%) 
8 (50.0) 
8 (50.0) 
0.3768 n (%) 
153 (33.9) 
298 (66.1) 
Cytoreduction 
   R0 
   R1 
   R2  
n (%) 
30 (96.8) 
1 (3.2) 
0 (0.0) 
n (%) 
34 (89.5) 
3 (7.9) 
1 (2.6) 
n (%) 
13 (81.3) 
2 (12.5) 
1 (6.3) 
0.5543 n (%) 
275 (61.0) 
67 (14.9) 
109 (24.2) 
Surgical  
complexity* 
   Low 
   Intermediate 
   High 
n (%)  
 
2 (6.5) 
10 (32.3) 
19 (61.3) 
n (%) 
 
2 (5.3) 
19 (50.0)  
17 (44.7) 
n (%) 
 
5 (31.3) 
6 (37.5) 
5 (31.3) 
0.0172 n (%) 
 
352 (78.0) 
83 (18.4) 
16 (3.5) 
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* Surgical complexity as per Aletti’s surgical complexity score [20]. 
 
 
 
 
 
Table 2: Identification of diaphragm disease with pre-operative imaging 
Disease 
identification 
Evidence intra-operatively No evidence intra-
operatively 
Predictive Value 
Suspicion on pre-
operative imaging 
66/507 (13.0%) 
 
18/507 (3.6%) PPV: 78.6% 
(66/84) 
No suspicion on 
pre-operative 
imaging 
149/507 (29.4%) 
 
274/507 (54.0%) NPV: 64.8% 
(274/423) 
 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
  
 
 
Table 3: Distribution of diaphragm disease in patients who underwent diaphragm resection 
and peritoneal stripping 
   
Distribution of diaphragm disease Diaphragm Resection 
n (%) 
Peritoneal stripping 
n (%) 
   
Peritoneal surface only 
Invasion into fibrous/adipose tissue 
Invasion into muscle  
Invasion into/through pleural surface 
6 (19.4) 
9 (29.0) 
4 (12.9) 
8 (25.8) 
14 (36.8) 
14 (36.8) 
5 (13.2) 
0 (0.0) 
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Table 4: Surgical procedures and associated morbidity 
 Diaphragmatic 
resection 
N=31 (36.5%) 
Peritoneal 
stripping 
N=38 (44.7%) 
Ablation / 
Minor resection  
N= 16 (18.9%) 
P Value 
Additional surgical 
procedures 
  Peritonectomy   
  (abdominal/pelvic) 
  Recto-sigmoid 
  resection 
  Appendicectomy 
  Splenectomy 
  Other bowel  
  resection  
  Lymphadenectomy 
  Cholecystectomy 
  Liver resection 
  Distal 
  pancreatectomy 
  Gastric resection 
n (%) 
 
24 (77.4) 
 
20 (64.5) 
 
11 (35.5) 
6 (19.4) 
6 (19.4) 
 
3 (9.7) 
1 (3.2) 
1 (3.2) 
1 (3.2) 
 
1 (3.2) 
n (%) 
 
33 (86.8) 
 
26 (68.4) 
 
5 (13.2) 
7 (18.4) 
7 (18.4) 
 
7 (18.4) 
2 (5.3) 
1 (2.6) 
1 (2.6) 
 
1 (2.6) 
n (%) 
 
9 (56.3) 
 
11 (68.8) 
 
3 (18.8) 
3 (18.8) 
1 (6.3) 
 
2 (12.5) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
0 (0.0) 
0.1780 
Highest grade** of  
complication 
   None 
   Grade 1 
   Grade 2 
   Grade 3a/3b 
   Grade 4a/4b 
n (%) 
  
13 (41.9) 
7 (22.6) 
6 (19.4) 
3 (9.7) 
1 (3.2) 
n (%) 
 
10 (26.3) 
5 (13.2) 
17 (44.7) 
5 (13.2) 
1 (2.6) 
n (%) 
 
4 (25.0) 
5 (31.3) 
5 (31.3) 
0 (0.0) 
1 (6.3) 
0.640 
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   Grade 5 1 (3.2) 0 (0.0) 1 (6.3) 
** Grade as per the Dindo grading system [18].  
 
 
 
 
 
Table 5: Details of grade 3 and 4 complications following diaphragm surgery 
 
Grade 3 complications  
 Pneumothorax requiring chest drain and bronchoscopy 
 Pleural effusion requiring drain insertion 
 CPAP for respiratory failure 
 Return to theatre for wound closure 
 Return to theatre for drainage of pelvic abscess 
 Return to theatre for refashion of colostomy with drainage of parastomal 
haematoma 
 Return to theatre due to stoma necrosis 
  
Grade 4 complications  
 Cerebral vascular accident 
 SIADH syndrome and acute renal failure 
 Return to theatre for stoma formation following failed anastomosis 
 Surgical intervention for intra-abdominal bleeding which necessitated a 
splenectomy 
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Table 6: Morbidity in patients following diaphragmatic surgery compared to matched controls 
Highest grade of  
Complication 
Diaphragmatic surgery 
 
n (%) 
Matched controls with no 
diaphragmatic surgery 
 n (%) 
P Value 
   None 
   Grade 1 
   Grade 2 
   Grade 3a/3b 
   Grade 4a/4b 
   Grade 5 
27 (31.8) 
17 (20.0) 
28 (32.9) 
8 (9.4) 
3 (3.5) 
2 (2.4) 
26 (30.6) 
18 (21.2)  
21 (24.7) 
12 (14.1) 
4 (4.7) 
4 (4.7) 
0.8728 
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